Antibody-drug conjugates (ADCs): an interview with Dr Marco Timmers, CSO at Synthon B
ADCs are used for a new type of targeted therapy that consists of a specific anti-cancer antibody or antibody fragment linked to a potent anti-cancer therapeutic.
More...
|